ArticleFrontiers in oncology2026
Investigating the mechanism of Fuzheng Sanjie Formula in regulating osimertinib resistance in NSCLC via the CAFs-TIMP3-MMP9 axis: a study integrating network pharmacology, data mining.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib resistance limits EGFR-mutant non-small cell lung cancer (NSCLC) treatment efficacy. Cancer-associated fibroblasts (CAFs), tissue inhibitor of metalloproteinases 3 (TIMP3), and matrix metalloproteinase 9 (MMP9) are involved in resistance. Fuzheng Sanjie Formula (FZSJF) is used clinically, but its mechanism is unclear. Objective: To explore the mechanism of FZSJF in reversing osimertinib resistance via the CAFs-TIMP3-MMP9 axis using network pharmacology, Methods: The main components of FZSJF were analyzed. Network pharmacology and molecular docking were used to assess binding to MMP9/TIMP3. TCGA data were used for expression and prognostic analysis. CompuSyn was used to calculate the combination index (CI) to assess whether the combination of osimertinib and FZSJF was synergistic Osimertinib-resistant cells (H1975OR) and CAFs were established and treated with control, osimertinib, FZSJF-containing serum, or their combination. Proliferation, invasion, migration, and MMP9/TIMP3 expression were evaluated by CCK-8, Transwell, wound healing, colony formation, Western blot (WB), quantitative real-time PCR (qPCR), and immunofluorescence (IF). TIMP3-silencing CAFs were co-cultured with H1975N cells to assess invasion and MMP9 expression. Nude mouse xenografts (H1975N, H1975OR, H1975N+CAFs) were used to evaluate tumor growth and protein expression. Results: MMP9 was identified as a key target. FZSJF components and osimertinib showed good binding to MMP9/TIMP3. TCGA revealed high MMP9 and low TIMP3 in lung cancer, with MMP9 linked to shorter overall survival (OS) and TIMP3 to longer OS. CI values confirmed synergy between osimertinib and FZSJF. H1975OR cells and CAFs showed upregulated MMP9 and downregulated TIMP3. FZSJF-containing serum inhibited the proliferation, invasion, and migration of H1975OR cells, upregulated TIMP3, and downregulated MMP9; when combined with osimertinib, these effects were enhanced. TIMP3-silencing CAFs promoted H1975N invasion and MMP9 expression. Conclusion: FZSJF reverses osimertinib resistance by upregulating TIMP3 and inhibiting CAFs-mediated MMP9 overexpression, restoring MMP9/TIMP3 balance and suppressing NSCLC invasion. This study provides experimental evidence for the efficacy of FZSJF in treating resistant NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.